1
|
Abstract
Even before the success of combined positron emission tomography and computed tomography (PET/CT), the neuroimaging community was conceiving the idea to integrate the positron emission tomography (PET), with very high molecular quantitative data but low spatial resolution, and magnetic resonance imaging (MRI), with high spatial resolution. Several technical limitations have delayed the use of a hybrid scanner in neuroimaging studies, including the full integration of the PET detector ring within the MRI system, the optimization of data acquisition, and the implementation of reliable methods for PET attenuation, motion correction, and joint image reconstruction. To be valid and useful in clinical and research settings, this instrument should be able to simultaneously acquire PET and MRI, and generate quantitative parametric PET images comparable to PET-CT. While post hoc co-registration of combined PET and MRI data acquired separately became the most reliable technique for the generation of "fused" PET-MRI images, only hybrid PET-MRI approach allows merging these measurements naturally and correlating them in a temporal manner. Furthermore, hybrid PET-MRI represents the most accurate tool to investigate in vivo the interplay between molecular and functional aspects of brain pathophysiology. Hybrid PET-MRI technology is still in the early stages in the movement disorders field, due to the limited availability of scanners with integrated optimized methodological models. This technology is ideally suited to investigate interactions between resting-state functional/arterial spin labeling MRI and [18F]FDG PET glucose metabolism in the evaluation of the brain "hubs" particularly vulnerable to neurodegeneration, areas with a high degree of connectivity and associated with an efficient synaptic neurotransmission. In Parkinson's disease, hybrid PET-MRI is also the ideal instrument to deeper explore the relationship between resting-state functional MRI and dopamine release at [11C]raclopride PET challenge, in the identification of early drug-naïve Parkinson's disease patients at higher risk of motor complications and in the evaluation of the efficacy of novel neuroprotective treatment able to restore at the same time the altered resting state and the release of dopamine. In this chapter, we discuss the key methodological aspects of hybrid PET-MRI; the evidence in movement disorders of the key resting-state functional and perfusion MRI; [18F]FDG PET and [11C]raclopride PET challenge studies; the potential advantages of using hybrid PET-MRI to investigate the pathophysiology of movement disorders and neurodegenerative diseases. Future directions of hybrid PET-MRI will be discussed alongside with up-to-date technological innovations on hybrid systems.
Collapse
|
2
|
Quantitative multimodal multiparametric imaging in Alzheimer's disease. Brain Inform 2016; 3:29-37. [PMID: 27747597 PMCID: PMC4883163 DOI: 10.1007/s40708-015-0028-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Accepted: 12/07/2015] [Indexed: 12/18/2022] Open
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, causing changes in memory, thinking, and other dysfunction of brain functions. More and more people are suffering from the disease. Early neuroimaging techniques of AD are needed to develop. This review provides a preliminary summary of the various neuroimaging techniques that have been explored for in vivo imaging of AD. Recent advances in magnetic resonance (MR) techniques, such as functional MR imaging (fMRI) and diffusion MRI, give opportunities to display not only anatomy and atrophy of the medial temporal lobe, but also at microstructural alterations or perfusion disturbance within the AD lesions. Positron emission tomography (PET) imaging has become the subject of intense research for the diagnosis and facilitation of drug development of AD in both animal models and human trials due to its non-invasive and translational characteristic. Fluorodeoxyglucose (FDG) PET and amyloid PET are applied in clinics and research departments. Amyloid beta (Aβ) imaging using PET has been recognized as one of the most important methods for the early diagnosis of AD, and numerous candidate compounds have been tested for Aβ imaging. Besides in vivo imaging method, a lot of ex vivo modalities are being used in the AD researches. Multiphoton laser scanning microscopy, neuroimaging of metals, and several metal bioimaging methods are also mentioned here. More and more multimodality and multiparametric neuroimaging techniques should improve our understanding of brain function and open new insights into the pathophysiology of AD. We expect exciting results will emerge from new neuroimaging applications that will provide scientific and medical benefits.
Collapse
|
3
|
Liu S, Cai W, Liu S, Zhang F, Fulham M, Feng D, Pujol S, Kikinis R. Multimodal neuroimaging computing: the workflows, methods, and platforms. Brain Inform 2015; 2:181-195. [PMID: 27747508 PMCID: PMC4737665 DOI: 10.1007/s40708-015-0020-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Accepted: 08/20/2015] [Indexed: 12/20/2022] Open
Abstract
The last two decades have witnessed the explosive growth in the development and use of noninvasive neuroimaging technologies that advance the research on human brain under normal and pathological conditions. Multimodal neuroimaging has become a major driver of current neuroimaging research due to the recognition of the clinical benefits of multimodal data, and the better access to hybrid devices. Multimodal neuroimaging computing is very challenging, and requires sophisticated computing to address the variations in spatiotemporal resolution and merge the biophysical/biochemical information. We review the current workflows and methods for multimodal neuroimaging computing, and also demonstrate how to conduct research using the established neuroimaging computing packages and platforms.
Collapse
Affiliation(s)
- Sidong Liu
- School of IT, The University of Sydney, Sydney, Australia.
| | - Weidong Cai
- School of IT, The University of Sydney, Sydney, Australia
| | - Siqi Liu
- School of IT, The University of Sydney, Sydney, Australia
| | - Fan Zhang
- School of IT, The University of Sydney, Sydney, Australia
- Surgical Planning Laboratory, Harvard Medical School, Boston, USA
| | - Michael Fulham
- Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Sydney Medical School, The University of Sydney, Sydney, Australia
| | - Dagan Feng
- School of IT, The University of Sydney, Sydney, Australia
- Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China
| | - Sonia Pujol
- Surgical Planning Laboratory, Harvard Medical School, Boston, USA
| | - Ron Kikinis
- Surgical Planning Laboratory, Harvard Medical School, Boston, USA
| |
Collapse
|
4
|
Liu S, Cai W, Liu S, Zhang F, Fulham M, Feng D, Pujol S, Kikinis R. Multimodal neuroimaging computing: a review of the applications in neuropsychiatric disorders. Brain Inform 2015; 2:167-180. [PMID: 27747507 PMCID: PMC4737664 DOI: 10.1007/s40708-015-0019-x] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2015] [Accepted: 08/08/2015] [Indexed: 12/20/2022] Open
Abstract
Multimodal neuroimaging is increasingly used in neuroscience research, as it overcomes the limitations of individual modalities. One of the most important applications of multimodal neuroimaging is the provision of vital diagnostic data for neuropsychiatric disorders. Multimodal neuroimaging computing enables the visualization and quantitative analysis of the alterations in brain structure and function, and has reshaped how neuroscience research is carried out. Research in this area is growing exponentially, and so it is an appropriate time to review the current and future development of this emerging area. Hence, in this paper, we review the recent advances in multimodal neuroimaging (MRI, PET) and electrophysiological (EEG, MEG) technologies, and their applications to the neuropsychiatric disorders. We also outline some future directions for multimodal neuroimaging where researchers will design more advanced methods and models for neuropsychiatric research.
Collapse
Affiliation(s)
- Sidong Liu
- School of IT, The University of Sydney, Sydney, Australia.
| | - Weidong Cai
- School of IT, The University of Sydney, Sydney, Australia
| | - Siqi Liu
- School of IT, The University of Sydney, Sydney, Australia
| | - Fan Zhang
- Surgical Planning Laboratory, Harvard Medical School, Boston, USA
| | - Michael Fulham
- Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, and the Sydney Medical School, The University of Sydney, Sydney, Australia
| | - Dagan Feng
- School of IT, The University of Sydney, Sydney, Australia
- Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China
| | - Sonia Pujol
- Surgical Planning Laboratory, Harvard Medical School, Boston, USA
| | - Ron Kikinis
- Surgical Planning Laboratory, Harvard Medical School, Boston, USA
| |
Collapse
|
5
|
Bisdas S, lá Fougere C, Ernemann U. Hybrid MR-PET in Neuroimaging. Clin Neuroradiol 2015; 25 Suppl 2:275-81. [DOI: 10.1007/s00062-015-0427-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 06/25/2015] [Indexed: 12/27/2022]
|
6
|
The added value of PET/Ce-CT/DW-MRI fusion in assessment of hepatic focal lesions: PET/Ce-CT/DW-MRI fusion in hepatic focal lesion. Nucl Med Biol 2015; 42:637-42. [PMID: 25907467 DOI: 10.1016/j.nucmedbio.2015.03.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Revised: 03/16/2015] [Accepted: 03/31/2015] [Indexed: 12/27/2022]
Abstract
INTRODUCTION The liver hosts a variety of benign and malignant tumors. Accurate diagnosis can be challenging in certain cases, especially in patients with a history of malignancy or in those with underlying liver pathology, such as cirrhosis. OBJECTIVES To evaluate the added clinical value of multi-modality liver imaging utilizing PET/Ce-CT/DW-MRI for characterization of hepatic focal lesions (HFL) and compare it with each diagnostic modality when interpreted alone. METHODS The study included 35 patients with HFL. They were 7 females & 28 males; their age ranged from 41 to 78years, all patients underwent PET/Ce-CT and DW-MRI scans. Ce-CT, PET and DW-MR images were reviewed independently, and then combined PET/Ce-CT, PET/DW-MRI and PET/Ce-CT/DW-MRI scans were analyzed. The results were correlated with histopathology or clinical/imaging follow-up. RESULTS The 35 patients had 98 focal lesions. Fifty-three lesions were finally diagnosed as primary hepatocellular carcinoma, 18 lesions were metastases, 7 lesions were lymphoma and 20 lesions were benign. On a patient based analysis; the sensitivity, specificity, PPV, NPV and accuracy were 100%, 67%, 94%, 100% and 94% for PET/Ce-CT compared to 97%, 83%, 97%, 83% and 94 % for DW-MRI, respectively. Combined PET/Ce-CT/DW-MR scans raise those parameters up to 100%. On a lesion based analysis; the sensitivity, specificity, PPV, NPV and accuracy were 94%, 75%, 94%, 75%, 90% for PET/Ce-CT compared to 94%, 95%, 99%, 97% and 94 % for DW-MRI, respectively. All these parameters were 100 % with PET/Ce-CT/DW-MRI. CONCLUSIONS The addition of DW-MRI to PET/Ce-CT is valuable in the characterization of hepatic focal lesions.
Collapse
|
7
|
Blumhagen JO, Braun H, Ladebeck R, Fenchel M, Faul D, Scheffler K, Quick HH. Field of view extension and truncation correction for MR-based human attenuation correction in simultaneous MR/PET imaging. Med Phys 2014; 41:022303. [PMID: 24506641 DOI: 10.1118/1.4861097] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
PURPOSE In quantitative PET imaging, it is critical to accurately measure and compensate for the attenuation of the photons absorbed in the tissue. While in PET/CT the linear attenuation coefficients can be easily determined from a low-dose CT-based transmission scan, in whole-body MR/PET the computation of the linear attenuation coefficients is based on the MR data. However, a constraint of the MR-based attenuation correction (AC) is the MR-inherent field-of-view (FoV) limitation due to static magnetic field (B0) inhomogeneities and gradient nonlinearities. Therefore, the MR-based human AC map may be truncated or geometrically distorted toward the edges of the FoV and, consequently, the PET reconstruction with MR-based AC may be biased. This is especially of impact laterally where the patient arms rest beside the body and are not fully considered. METHODS A method is proposed to extend the MR FoV by determining an optimal readout gradient field which locally compensates B0 inhomogeneities and gradient nonlinearities. This technique was used to reduce truncation in AC maps of 12 patients, and the impact on the PET quantification was analyzed and compared to truncated data without applying the FoV extension and additionally to an established approach of PET-based FoV extension. RESULTS The truncation artifacts in the MR-based AC maps were successfully reduced in all patients, and the mean body volume was thereby increased by 5.4%. In some cases large patient-dependent changes in SUV of up to 30% were observed in individual lesions when compared to the standard truncated attenuation map. CONCLUSIONS The proposed technique successfully extends the MR FoV in MR-based attenuation correction and shows an improvement of PET quantification in whole-body MR/PET hybrid imaging. In comparison to the PET-based completion of the truncated body contour, the proposed method is also applicable to specialized PET tracers with little uptake in the arms and might reduce the computation time by obviating the need for iterative calculations of the PET emission data beyond those required for reconstructing images.
Collapse
Affiliation(s)
- Jan O Blumhagen
- Magnetic Resonance, Siemens AG Healthcare Sector, Erlangen 91052, Germany
| | - Harald Braun
- Institute of Medical Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91052, Germany
| | - Ralf Ladebeck
- Magnetic Resonance, Siemens AG Healthcare Sector, Erlangen 91052, Germany
| | - Matthias Fenchel
- Magnetic Resonance, Siemens AG Healthcare Sector, Erlangen 91052, Germany
| | - David Faul
- Siemens Medical Solutions, New York, New York 10015
| | - Klaus Scheffler
- MRC Department, Max Planck Institute for Biological Cybernetics, Tübingen 72076, Germany and Department of Biomedical Magnetic Resonance, University Hospital Tübingen, Tübingen 72076, Germany
| | - Harald H Quick
- Institute of Medical Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91052, Germany
| |
Collapse
|
8
|
Xiong L, Engel H, Gazyakan E, Rahimi M, Hünerbein M, Sun J, Kneser U, Hirche C. Current techniques for lymphatic imaging: State of the art and future perspectives. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 2014; 40:270-6. [DOI: 10.1016/j.ejso.2013.11.027] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Revised: 11/10/2013] [Accepted: 11/29/2013] [Indexed: 10/25/2022]
|
9
|
Thorwarth D, Müller AC, Pfannenberg C, Beyer T. Combined PET/MR imaging using (68)Ga-DOTATOC for radiotherapy treatment planning in meningioma patients. Recent Results Cancer Res 2013; 194:425-439. [PMID: 22918773 DOI: 10.1007/978-3-642-27994-2_23] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Hybrid imaging is beneficial for improved medical diagnosis and therapy planning today. Hybrid imaging describes the prospective correlation of two or more complementary sets of imaging information, such as functional and anatomical image volumes. Correlation can be performed through physically combined imaging modalities, such as PET/CT, SPECT/CT, or PET/MR. Here we present first results from employing fully integrated PET/MR tomography for intensity-modulated radiotherapy (IMRT) treatment planning in patients with meningioma using [(68)Ga]-DOTATOC as the biomarker of choice. Combined PET/MR offers higher soft tissue contrast and the ability to add functional information to the plain combination of MR-based anatomy and PET-based metabolic and molecular information. Furthermore, fully integrated PET/MR employs novel PET technology that is neither available in PET-only nor PET/CT systems. Despite the current lack of broad clinical evidence, integrated PET/MR may become particularly important and clinically useful for improved, individualized RT therapy planning for brain lesions. In particular, logistical and diagnostic benefits of integrated PET/MR-based treatment planning over treatment planning based on PET/CT data may be expected in meningioma patients.
Collapse
Affiliation(s)
- Daniela Thorwarth
- University Hospital for Radiation Oncology, Eberhard-Karls-University Tübingen, Tübingen, Germany.
| | | | | | | |
Collapse
|
10
|
Blumhagen JO, Ladebeck R, Fenchel M, Scheffler K. MR-based field-of-view extension in MR/PET:B0homogenization using gradient enhancement (HUGE). Magn Reson Med 2012. [DOI: 10.1002/mrm.24555] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Jan O. Blumhagen
- Magnetic Resonance; Healthcare Sector; Siemens AG; Erlangen Germany
- Division of Radiological Physics; University of Basel Hospital; Basel Switzerland
| | - Ralf Ladebeck
- Magnetic Resonance; Healthcare Sector; Siemens AG; Erlangen Germany
| | - Matthias Fenchel
- Magnetic Resonance; Healthcare Sector; Siemens AG; Erlangen Germany
| | - Klaus Scheffler
- Division of Radiological Physics; University of Basel Hospital; Basel Switzerland
- MRC Department; Max Planck Institute for Biological Cybernetics; Tuebingen Germany
- Department of Biomedical Magnetic Resonance; University Hospital Tuebingen; Tuebingen Germany
| |
Collapse
|
11
|
Abstract
Over the last few decades it has been shown that novel technologies and technological progress rapidly change the working environment of radiologists and nuclear medicine physicians. Thus, new possibilities, e.g., in tumor staging and therapy monitoring, but also new challenges arise. Recently, it could be shown that the integration of magnetic resonance imaging (MRI) and positron emission tomography (PET) is technically possible. The evolvement of new dedicated hybrid MR/PET systems for whole-body imaging in humans offers new potential in multimodal imaging. Especially simultaneous measurement of PET and MRI datasets allows for insights in metabolic and functional processes, particularly in oncologic demands, but also in cardiovascular and cerebral imaging. In this work-in-progress review article, a technical summary including the method-inherent challenges are given. Furthermore, possible clinical applications and research interests are addressed.
Collapse
|
12
|
Schwenzer NF, Stegger L, Bisdas S, Schraml C, Kolb A, Boss A, Müller M, Reimold M, Ernemann U, Claussen CD, Pfannenberg C, Schmidt H. Simultaneous PET/MR imaging in a human brain PET/MR system in 50 patients--current state of image quality. Eur J Radiol 2012; 81:3472-8. [PMID: 22260898 DOI: 10.1016/j.ejrad.2011.12.027] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2011] [Revised: 12/14/2011] [Accepted: 12/15/2011] [Indexed: 11/26/2022]
Abstract
OBJECTIVES The present work illustrates the current state of image quality and diagnostic accuracy in a new hybrid BrainPET/MR. MATERIALS AND METHODS 50 patients with intracranial masses, head and upper neck tumors or neurodegenerative diseases were examined with a hybrid BrainPET/MR consisting of a conventional 3T MR system and an MR-compatible PET insert. Directly before PET/MR, all patients underwent a PET/CT examination with either [18F]-FDG, [11C]-methionine or [68Ga]-DOTATOC. In addition to anatomical MR scans, functional sequences were performed including diffusion tensor imaging (DTI), arterial spin labeling (ASL) and proton-spectroscopy. Image quality score of MR imaging was evaluated using a 4-point-scale. PET data quality was assessed by evaluating FDG-uptake and tumor delineation with [11C]-methionine and [68Ga]-DOTATOC. FDG uptake quantification accuracy was evaluated by means of ROI analysis (right and left frontal and temporo-occipital lobes). The asymmetry indices and ratios between frontal and occipital ROIs were compared. RESULTS In 45/50 patients, PET/MR examination was successful. Visual analysis revealed a diagnostic image quality of anatomical MR imaging (mean quality score T2 FSE: 1.27±0.54; FLAIR: 1.38±0.61). ASL and proton-spectroscopy was possible in all cases. In DTI, dental artifacts lead to one non-diagnostic dataset (mean quality score DTI: 1.32±0.69; ASL: 1.10±0.31). PET datasets of PET/MR and PET/CT offered comparable tumor delineation with [11C]-methionine; additional lesions were found in 2/8 [(68)Ga]-DOTATOC-PET in the PET/MR. Mean asymmetry index revealed a high accordance between PET/MR and PET/CT (1.5±2.2% vs. 0.9±3.6%; mean ratio (frontal/parieto-occipital) 0.93±0.08 vs. 0.96±0.05), respectively. CONCLUSIONS The hybrid BrainPET/MR allows for molecular, anatomical and functional imaging with uncompromised MR image quality and a high accordance of PET results between PET/MR and PET/CT. These results justify the application of this technique in further clinical studies and may contribute to the transfer into whole-body PET/MR systems.
Collapse
Affiliation(s)
- N F Schwenzer
- Department of Diagnostic and Interventional Radiology, Eberhard-Karls University Tübingen, Tübingen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
Early diagnosis and therapy increasingly operate at the cellular, molecular, or even at the genetic level. As diagnostic techniques transition from the systems to the molecular level, the role of multimodality molecular imaging becomes increasingly important. Positron emission tomography (PET) and magnetic resonance imaging (MRI) are powerful techniques for in vivo molecular imaging. The inability of PET to provide anatomical information is a major limitation of standalone PET systems. Combining PET and CT proved to be clinically relevant and successfully reduced this limitation by providing the anatomical information required for localization of metabolic abnormalities. However, this technology still lacks the excellent soft-tissue contrast provided by MRI. Standalone MRI systems reveal structure and function but cannot provide insight into the physiology and/or the pathology at the molecular level. The combination of PET and MRI, enabling truly simultaneous acquisition, bridges the gap between molecular and systems diagnosis. MRI and PET offer richly complementary functionality and sensitivity; fusion into a combined system offering simultaneous acquisition will capitalize the strengths of each, providing a hybrid technology that is greatly superior to the sum of its parts. A combined PET/MRI system provides both the anatomical and structural description of MRI simultaneously with the quantitative capabilities of PET. In addition, such a system would allow exploiting the power of MR spectroscopy (MRS) to measure the regional biochemical content and to assess the metabolic status or the presence of neoplasia and other diseases in specific tissue areas. This paper briefly summarizes state-of-the-art developments and latest advances in dedicated hybrid PET/MRI instrumentation. Future prospects and potential clinical applications of this technology will also be discussed.
Collapse
Affiliation(s)
- Habib Zaidi
- Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva, Switzerland.
| | | |
Collapse
|
14
|
Beyer T, Freudenberg LS, Czernin J, Townsend DW. The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Imaging 2011; 2:235-246. [PMID: 22347950 PMCID: PMC3270262 DOI: 10.1007/s13244-011-0085-4] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2010] [Revised: 01/04/2011] [Accepted: 02/18/2011] [Indexed: 11/30/2022] Open
Abstract
Since the 1990s, hybrid imaging by means of software and hardware image fusion alike allows the intrinsic combination of functional and anatomical image information. This review summarises in three parts the state of the art of dual-technique imaging with a focus on clinical applications. We will attempt to highlight selected areas of potential improvement of combined imaging technologies and new applications. In this third part, we discuss briefly the origins of combined positron emission tomography (PET)/magnetic resonance imaging (MRI). Unlike PET/computed tomography (CT), PET/MRI started out from developments in small-animal imaging technology, and, therefore, we add a section on advances in dual- and multi-modality imaging technology for small animals. Finally, we highlight a number of important aspects beyond technology that should be addressed for a sustained future of hybrid imaging. In short, we predict that, within 10 years, we may see all existing multi-modality imaging systems in clinical routine, including PET/MRI. Despite the current lack of clinical evidence, integrated PET/MRI may become particularly important and clinically useful in improved therapy planning for neurodegenerative diseases and subsequent response assessment, as well as in complementary loco-regional oncology imaging. Although desirable, other combinations of imaging systems, such as single-photon emission computed tomography (SPECT)/MRI may be anticipated, but will first need to go through the process of viable clinical prototyping. In the interim, a combination of PET and ultrasound may become available. As exciting as these new possible triple-technique—imaging systems sound, we need to be aware that they have to be technologically feasible, applicable in clinical routine and cost-effective.
Collapse
Affiliation(s)
- Thomas Beyer
- cmi-experts GmbH, Pestalozzistr 3, 8032 Zürich, Switzerland
- Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
| | - Lutz S. Freudenberg
- Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
- Department of Nuclear Medicine, ZRN, Grevenbroich, Germany
| | - Johannes Czernin
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA USA
| | - David W. Townsend
- Singapore Bioimaging Consortium, 11 Biopolis Way, 02-02 Helios, Singapore, 138667 Singapore
| |
Collapse
|